Literature DB >> 16477625

Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues.

Salvatore Ulisse1, Jean-Guy Delcros, Enke Baldini, Matteo Toller, Francesco Curcio, Laura Giacomelli, Claude Prigent, Francesco S Ambesi-Impiombato, Massimino D'Armiento, Yannick Arlot-Bonnemains.   

Abstract

The Aurora kinases are involved in the regulation of cell cycle progression, and alterations in their expression have been shown to associate with cell malignant transformation. In the present study, we demonstrated that human thyrocytes express all 3 Aurora kinases (A, B and C) at both protein and mRNA level and this expression is cell cycle-regulated. An increase in the protein level of the 3 kinases was found, with respect to normal human thyrocytes (HTU5), in the human cell lines derived from follicular (FTC-133), papillary (B-CPAP) and anaplastic (8305C) thyroid carcinomas, but not in cells derived from a follicular adenoma (HTU42). These observations were mirrored in RT-PCR experiments for Aurora-A and B. In contrast, Aurora-C mRNA levels were not significantly different among the different cell types analyzed, suggesting that posttranscriptional mechanism(s) modulate its expression. The expression at the protein level of all 3 Aurora kinases was significantly higher in 3 thyroid papillary carcinomas with respect to normal matched tissues obtained from the same patients. Similar modifications, at the mRNA level, could be observed in 7 papillary carcinoma tissues for Aurora-A and B, but not for Aurora-C. In conclusion, we demonstrated that normal human thyrocytes express all 3 members of the Aurora kinase family, and their expression is amplified in malignant thyroid cell lines and tissues. These results suggest that the Aurora kinases may play a relevant role in malignant thyroid cancers, and may represent a putative therapeutic target for thyroid neoplasms. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16477625     DOI: 10.1002/ijc.21842

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  32 in total

Review 1.  Cdk1, Plks, Auroras, and Neks: the mitotic bodyguards.

Authors:  Patrick Salaun; Yoann Rannou; Claude Prigent
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 2.  Anaplastic thyroid cancer, tumorigenesis and therapy.

Authors:  J P O'Neill; D Power; C Condron; D Bouchier-Hayes; M Walsh
Journal:  Ir J Med Sci       Date:  2009-08-07       Impact factor: 1.568

3.  Structural studies of B-type Aurora kinase inhibitors using computational methods.

Authors:  Mm Neaz; M Muddassar; Fa Pasha; Seung Joo Cho
Journal:  Acta Pharmacol Sin       Date:  2010-02       Impact factor: 6.150

4.  Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells.

Authors:  Shih-Che Hua; Tien-Chun Chang; Hau-Ren Chen; Chieh-Hsiang Lu; Yi-Wen Liu; Shu-Hsin Chen; Hui-I Yu; Yi-Ping Chang; Ying-Ray Lee
Journal:  Pharm Res       Date:  2012-04-04       Impact factor: 4.200

5.  Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.

Authors:  Ali Zekri; Seyed H Ghaffari; Marjan Yaghmaie; Mehrdad Asghari Estiar; Kamran Alimoghaddam; Mohammad Hossein Modarressi; Ardeshir Ghavamzadeh
Journal:  Mol Neurobiol       Date:  2015-03-11       Impact factor: 5.590

6.  Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.

Authors:  Mari Kogiso; Lin Qi; Frank K Braun; Sarah G Injac; Linna Zhang; Yuchen Du; Huiyuan Zhang; Frank Y Lin; Sibo Zhao; Holly Lindsay; Jack M Su; Patricia A Baxter; Adekunle M Adesina; Debra Liao; Mark G Qian; Stacey Berg; Jodi A Muscal; Xiao-Nan Li
Journal:  Clin Cancer Res       Date:  2018-02-20       Impact factor: 12.531

Review 7.  Mitotic failures in cancer: Aurora B kinase and its potential role in the development of aneuploidy.

Authors:  Katalin Hegyi; Gábor Méhes
Journal:  Pathol Oncol Res       Date:  2012-07-29       Impact factor: 3.201

Review 8.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

9.  Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients.

Authors:  Yi-Jen Chen; Chun-Ming Chen; Nae-Fang Twu; Ming-Shyen Yen; Chiung-Ru Lai; Hua-Hsi Wu; Peng-Hui Wang; Chiou-Chung Yuan
Journal:  Virchows Arch       Date:  2009-10-17       Impact factor: 4.064

10.  Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.

Authors:  Chiara Tuccilli; Enke Baldini; Natalie Prinzi; Stefania Morrone; Salvatore Sorrenti; Angelo Filippini; Antonio Catania; Stefania Alessandrini; Roberta Rendina; Carmela Coccaro; Massimino D'Armiento; Salvatore Ulisse
Journal:  Endocrine       Date:  2015-07-28       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.